摘要
心功能Ⅱ—Ⅲ级的慢性心衰患者,使用β受体阻断药能明显降低死亡率。Ⅳ级的重度心衰患者是否也能从β受体阻断药治疗中受益呢?本文分析了MERIT－HF亚组、CIBIS－Ⅱ、COPERNICUS等研究。结果表明,相对稳定的重度心衰患者使用β受体阻断药后,能使包括总死亡率在内的诸项有关生存率的指标改善。使用β受体阻断药时,开始给予小药量,逐渐增加(一般每2周加倍)至靶剂量,相对稳定的重度心衰患者不但能良好耐受,而且,心功能逐渐得到明显改善。对不稳定的重度心衰患者,应否及早使用β受体阻断药等有待进一步研究。
Beta-blocker can reduce the mortality maredly in patients suffering fromchronic heart failure with NYHA classⅡ~Ⅲ cardiac function. Whether beta-blocker will benefit patients with class Ⅳ cardiac function? In this review, weanalyzed the MERIT-HF (sub-group), CIBIS-Ⅱ, COPERNICUS:and other clinicaltrials and reached conclusions as follows: After the treatment of beta-blocker, totalmortality and other indices of survival were improved in patients with severe heartfailure. With beta-blocker given a very low dose at the beginning and increasedgradually (usually double every 2 weeks) to the target dosage, patients with severeheart failure could not only tolerate the drug well, but also experienced improvementof heart function. There should be further studies to get an answer to the questionof whether beta-blocker therapy should be commenced eary in patients with severe,unstable heart failure.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2002年第2期153-155,共3页
The Chinese Journal of Clinical Pharmacology
